Malaria - Pipeline Review, H2 2016

Date: November 16, 2016
Pages: 413
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: ME58845C40CEN
Leaflet:

Download PDF Leaflet

Malaria - Pipeline Review, H2 2016
Malaria - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Malaria – Pipeline Review, H2 2016, provides an overview of the Malaria (Infectious Disease) pipeline landscape.

Malaria is a life-threatening blood disease caused by a parasite (Plasmodium) that is transmitted to humans by the Anopheles mosquito. People at increased risk of serious disease include young children and infants, travelers coming from areas with no malaria and pregnant women and their unborn children. Symptoms may include fever, chills, headache, sweats, fatigue, enlarged spleen, nausea and vomiting. Treatment includes anti-malarial medicines and healthy lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Malaria – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Malaria (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Malaria (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Malaria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 12, 7, 62 and 29 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 14, 46 and 41 molecules, respectively.Malaria.

Malaria (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Malaria (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Malaria (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Malaria (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Malaria (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Malaria (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Malaria (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Malaria (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Malaria Overview
Therapeutics Development
Malaria - Therapeutics under Development by Companies
Malaria - Therapeutics under Investigation by Universities/Institutes
Malaria - Pipeline Products Glance
Malaria - Products under Development by Companies
Malaria - Products under Investigation by Universities/Institutes
Malaria - Companies Involved in Therapeutics Development
Malaria - Therapeutics Assessment
Drug Profiles
Malaria - Dormant Projects
Malaria - Discontinued Products
Malaria - Product Development Milestones
Appendix 390

LIST OF TABLES

Number of Products under Development for Malaria, H2 2016
Number of Products under Development for Malaria - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..4)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..5)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..6)
Malaria - Pipeline by 4SC AG, H2 2016
Malaria - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016
Malaria - Pipeline by Actelion Ltd, H2 2016
Malaria - Pipeline by Agilvax Inc, H2 2016
Malaria - Pipeline by Akshaya Bio Inc., H2 2016
Malaria - Pipeline by Allergy Therapeutics Plc, H2 2016
Malaria - Pipeline by Amura Holdings Limited, H2 2016
Malaria - Pipeline by Anacor Pharmaceuticals, Inc., H2 2016
Malaria - Pipeline by Artificial Cell Technologies, Inc., H2 2016
Malaria - Pipeline by AstraZeneca Plc, H2 2016
Malaria - Pipeline by Bharat Biotech International Limited, H2 2016
Malaria - Pipeline by Callaghan Innovation Research Ltd., H2 2016
Malaria - Pipeline by Carna Biosciences, Inc., H2 2016
Malaria - Pipeline by CEL-SCI Corporation, H2 2016
Malaria - Pipeline by Celgene Corporation, H2 2016
Malaria - Pipeline by Cellceutix Corporation, H2 2016
Malaria - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016
Malaria - Pipeline by Cilian AG, H2 2016
Malaria - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
Malaria - Pipeline by DesignMedix, Inc., H2 2016
Malaria - Pipeline by Eisai Co., Ltd., H2 2016
Malaria - Pipeline by GenVec, Inc., H2 2016
Malaria - Pipeline by Genzyme Corporation, H2 2016
Malaria - Pipeline by GlaxoSmithKline Plc, H2 2016
Malaria - Pipeline by Hager Biosciences, LLC, H2 2016
Malaria - Pipeline by Horizon Pharma Plc, H2 2016
Malaria - Pipeline by iBio, Inc., H2 2016
Malaria - Pipeline by Imaxio SA, H2 2016
Malaria - Pipeline by Immtech Pharmaceuticals, Inc., H2 2016
Malaria - Pipeline by Immunovaccine Inc, H2 2016
Malaria - Pipeline by IPCA Laboratories Limited, H2 2016
Malaria - Pipeline by IRBM Science Park SpA, H2 2016
Malaria - Pipeline by Jenrin Discovery, Inc., H2 2016
Malaria - Pipeline by Jomaa Pharma GmbH, H2 2016
Malaria - Pipeline by Kancera AB, H2 2016
Malaria - Pipeline by Kymab Limited, H2 2016
Malaria - Pipeline by Lipocure Ltd., H2 2016
Malaria - Pipeline by Lipotek Pty Ltd., H2 2016
Malaria - Pipeline by LondonPharma Ltd, H2 2016
Malaria - Pipeline by Merck & Co., Inc., H2 2016
Malaria - Pipeline by Merck KGaA, H2 2016
Malaria - Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2016
Malaria - Pipeline by Microbiotix, Inc., H2 2016
Malaria - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
Malaria - Pipeline by Mucosis B.V., H2 2016
Malaria - Pipeline by Mymetics Corporation, H2 2016
Malaria - Pipeline by Novartis AG, H2 2016
Malaria - Pipeline by PaxVax, Inc., H2 2016
Malaria - Pipeline by Pfenex Inc., H2 2016
Malaria - Pipeline by Pfizer Inc., H2 2016
Malaria - Pipeline by Protein Potential, LLC, H2 2016
Malaria - Pipeline by Rodos BioTarget GmbH, H2 2016
Malaria - Pipeline by Sanaria Inc., H2 2016
Malaria - Pipeline by Sanofi, H2 2016
Malaria - Pipeline by SBI Pharmaceuticals Co., Ltd., H2 2016
Malaria - Pipeline by Selecta Biosciences, Inc., H2 2016
Malaria - Pipeline by Sigma-Tau S.p.A., H2 2016
Malaria - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Malaria - Pipeline by Telormedix SA, H2 2016
Malaria - Pipeline by Tomegavax, Inc., H2 2016
Malaria - Pipeline by VLP Biotech, Inc., H2 2016
Malaria - Pipeline by VLP Therapeutics, LLC, H2 2016
Malaria - Pipeline by Zydus Cadila Healthcare Limited, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Malaria - Dormant Projects, H2 2016
Malaria - Dormant Projects (Contd..1), H2 2016
Malaria - Dormant Projects (Contd..2), H2 2016
Malaria - Dormant Projects (Contd..3), H2 2016
Malaria - Dormant Projects (Contd..4), H2 2016
Malaria - Dormant Projects (Contd..5), H2 2016
Malaria - Dormant Projects (Contd..6), H2 2016
Malaria - Dormant Projects (Contd..7), H2 2016
Malaria - Dormant Projects (Contd..8), H2 2016
Malaria - Dormant Projects (Contd..9), H2 2016
Malaria - Dormant Projects (Contd..10), H2 2016
Malaria - Dormant Projects (Contd..11), H2 2016
Malaria - Dormant Projects (Contd..12), H2 2016
Malaria - Discontinued Products, H2 2016
Malaria - Discontinued Products (Contd..1), H2 2016 398

LIST OF FIGURES

Number of Products under Development for Malaria, H2 2016
Number of Products under Development for Malaria - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Malaria - Pipeline Review, H1 2016 US$ 2,000.00 May, 2016 · 423 pages
Seek - Product Pipeline Review - 2014 US$ 1,125.00 Oct, 2014 · 42 pages
Amura Holdings Ltd. - Product Pipeline Review - 2015 US$ 1,200.00 Apr, 2015 · 22 pages
DesignMedix, Inc. - Product Pipeline Review - 2015 US$ 1,275.00 Dec, 2015 · 20 pages
Mucosis B.V. - Product Pipeline Review - 2015 US$ 1,200.00 Jul, 2015 · 27 pages

Ask Your Question

Malaria - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: